Skip to main content
Premium Trial:

Request an Annual Quote

Certara, C-Path Partner on Testing Models for Tuberculosis Drugs

NEW YORK (GenomeWeb News) – Certara said this week that it is working with the Critical Path Institute, C-Path, to create a physiologically-based pharmacokinetic model of the human lung using Certara's Simcyp Population-based simulator software that will be used to test new tuberculosis drugs.

According to the partners, the model will be useful for predicting the disposition of drugs within the lungs and the potential impact of disease progression on drug kinetics at different stages of TB infection.

Drug developers can use it to "define dose regimens that will produce clinical concentrations of anti-TB drugs at target sites in the lungs, and help to expedite the development of new TB treatments," C-Path President and CEO Martha Brumfield said in a statement.

They can also use it to " simulate a wide range of variables in terms of drug dose, disease state, and concomitant medications for a much more efficient clinical trial design process," Daniel Weiner, Certara's senior vice president and general manager, said.

This partnership is supported by the Critical Path to TB Drug Regimens, or CPTR, Initiative, a coalition of pharmaceutical companies; government, regulatory, and multilateral agencies; academia; advocacy groups; and non-government organizations. It aims to develop new, safe, and highly effective TB treatment regimens with shorter therapy durations.